Imipenem+Relebactam

DRUG2 trials

Sponsors

Wake Forest University Health Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Conditions

Antibiotic Resistant InfectionCRE ColonizationCarbapenem-Resistant Enterobacteriaceae InfectionCarbapenem-resistant EnterobacteralesGram-Negative Bacterial InfectionsKPCLiver Transplant

Phase 3

Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

Not yet recruitingNCT07759453

IRCCS Azienda Ospedaliero-Universitaria di BolognaLiver Transplant, Carbapenem-resistant Enterobacterales, CRE Colonization

Start: 2026-10-01End: 2029-09-30Target: 168Updated: 2026-08-12

Phase 4

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

WithdrawnNCT04785924

Wake Forest University Health SciencesCarbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections +1

Start: 2021-06-07End: 2023-01-12Updated: 2024-09-04